Sequential changes in the humoral immune response of pigs to pseudorabies virus (PRV) after each of several exposures to the virus were evaluated by determining virus neutralization (VN) and radioimmunoprecipitation (RIP) activities of sera collected at selected intervals. Pigs were vaccinated intramuscularly with live attenuated virus (6 pigs), inactivated attenuated virus (6 pigs), or inactivated virulent virus (6 pigs). All pigs were challenged oronasally with virulent virus 3 weeks later and 12 (4 pigs of each vaccine group) were subsequently treated with dexamethasone in an attempt to reactivate latent virus.
Pseudorabies virus (PRV), an alpha herpesvirus, is a common pathogen of pigs and a threat to efficient pig production throughout most of the world. The consequences of infection depend on the interplay of a variety of factors reflecting both host susceptibility and virus virulence and range from acute illness and death to subclinical infection and immunity. 3 Pigs that survive their initial exposure to virulent PRV are often, if not always, latently infected and are potential shedders of virulent virus if latent virus is subsequently reactivated. 2, 20 Therefore, asymptomatic carriers are an integral facet of the epizootiology of pseudorabies and are believed by many to be the major obstacle to success of proposed pseudorabies eradication programs. 21, 26 Vaccination for pseudorabies is common, and in general, both attenuated and inactivated vaccines prevent severe clinical signs and death that are often associated with exposure of nonimmune pigs to virulent PRV. 3 However, none of the current vaccines are known to prevent either latent infection with virulent virus or subsequent reactivation and shedding. 2,4,8,l5,24,28 For this reason, several deletion-mutant PRV vaccines have been developed so that vaccinated pigs can be differentiated from pigs infected with virulent "wild type" virus. 7,9~25,26 Differentiation is based on the use of a companion diagnostic antigen; namely, a virus-coded protein(s) for which the deletion-mutant is defective.
Most studies of the humoral immune response of pigs to PRV have focused on the presence and titer of antibodies that either are associated with protection from clinical disease or are the basis for various diagnostic tests. devoted to assessing the immune response to the full complement of virus-coded proteins despite the potential contribution of such information to a better understanding of the pathogenesis of PRV, especially in regard to virus latency, reactivation, and shedding. Moreover, the suitability of a deletion-mutant vaccine depends on selection of a protein that is sufficiently antigenic to raise a detectable and persistent level of antibody even in vaccinated pigs naturally exposed to a minimum dose of virulent virus.
In this report, we describe the sequential changes in humoral immunity of pigs to PRV following vaccination with either attenuated or inactivated virus, challenge exposure to virulent virus, and reactivation of latent virus. Patterns of immunoreactivity, as determined by radioimmunoprecipitation (RIP) of PRVinfected cell lysates, are correlated with virus-neutralization (VN) activity and the incidence and duration of virus shedding following reactivation of latent virus.
Materials and methods
Pigs. Pigs used for experiment 1 were farm raised and were delivered to the National Animal Disease Center (NADC) shortly before the experiment was started. Those of experiment 2 were from 2 cesarean-derived colostrum-deprived (CDCD) litters that were raised in isolation at the NADC. All were from the same commercial herd in which none of the pigs was either vaccinated or known to be infected with PRV. All of the pigs used in the study were free of VN antibodies for PRV at the time they were vaccinated.
Cell cultures. Established porcine kidney cell lines, PK-15 and Mengeling Vaughn (MVPK-1), were used to propagate and identify PRV. Nutrient medium was Eagle's minimal essential medium (EMEM) supplemented with 0.25% lactalbumin hydrolysate (LAH), gentamicin sulfate (50 µg/ ml), and either 5% (PK-15) or 10% (MVPK-1) fetal bovine serum (FBS). When cultures were used to test nasal and tonsil swabs for virus, the medium was also supplemented with Amphotericin B (2 µg/ml).
Virus. Both attenuated and virulent strains of PRV were used in the study. The attenuated strain was from a locally purchased commercial vaccine. a The virulent strain (Indiana-Funkhauser) was from the virus repository maintained at the NADC.
Vaccine preparation. Separate batches of vaccine were prepared for each of 2 experiments. The attenuated strain of PRV was used to prepare both live-virus vaccine and inactivated-virus vaccine. The virulent strain of PRV was used to prepare inactivated-virus vaccine. Virus was propagated in MVPK-1 cells in flasks for experiment 1 and PK-15 cells in roller bottles for experiment 2. After monolayers reached confluency, the complete nutrient medium was aspirated and replaced with EMEM containing 0.25% LAH and gentamicin sulfate (50 &ml). Virus was added at a multiplicity of infection (MOI) of ≤ 0.01, and cultures were incubated at 37 C until virus-induced cytopathic effects (CPE) were essentially complete. The mixture of virus and cell debris was frozen and thawed and then titrated for infectivity. Plaque forming units (pfu)/ml were as follows: experiment 1, attenuated virus 10 7.2 , virulent virus 10 7.0 ; experiment 2, attenuated virus 10 8.6 virulent virus 10 8.8 . In each experiment, an aliquot of the attenuated virus was diluted to contain about 104.0 pfu/ml and was used at that concentration as live-virus vaccine. The preparation of inactivated vaccines was completed by adding 0.3% acetylethyleneimine to undiluted virus, incubating the mixture at 37 C for 4 hr, and then adding Al(OH) 3 to a final concentration of 10% as an adjuvant. Before the addition of adjuvant, an aliquot of vaccine was dialyzed and tested for infectious virus to confirm complete inactivation of infectivity. Attenuated-virus vaccine and inactivated-virus vaccines were stored at -80 C and 5 C, respectively.
Virus neutralization. Sera were tested for neutralizing activity against the virulent strain of PRV. Additions and dilutions of reagents were accomplished with the aid of an automated system. b Sera were diluted 2-fold in EMEM in 96-well cell culture plates' so that each of 4 wells contained 50 µl of each serum dilution. About 100 pfu of virus, in 50 µ1 of EMEM, was added to each well, and after mixing of virus and serum, plates were incubated at 37 C for 2 hr in a humid atmosphere of 5% CO,. About 5,000 MVPK-1 cells, in 100 µ1 of nutrient medium containing 20% FBS, were added to each well, and plates were again incubated at 37 C in a humid atmosphere of 5% CO,. Plates were examined daily for CPE, and the VN titer was expressed as the maximum initial dilution of serum, i.e., before adding virus and cells, that protected cells in at least 2 of the 4 wells.
Preparation of radio-labeled viral antigens. Cell cultures (PK-15) were grown in 28-cm 2 petri dishes at 37 C in a humid environment containing 5% CO,. Nutrient medium was aspirated after monolayers reached confluency, and either the attenuated strain or the virulent strain of PRV was added at an MOI of about 10. After 1 hr of incubation at 37 C, the inoculum was aspirated, and fresh nutrient medium was added. After 5 hr of incubation at 37 C, nutrient medium was replaced with either methionine-free EMEM containing 40 µCi/ml of 35 S-methionine (>1,000 Ci/mM) or EMEM containing 5 µCi/ml of 14 C-glucosamine hydrochloride (250-350 mCi/mM), and cultures were again incubated at 37 C. Between 12 and 18 hr later, the culture medium was aspirated and that from cultures labeled with 14 C-glucosamine hydrochloride was saved and subsequently used to test sera for precipitating antibody to the major secreted viral glycoprotein, gX. 9 The monolayer was then rinsed twice with wash buffer (150 mM NaCl, 5 mM Tris-HCl, 5 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, pH 7.2 at 25 C) and lysed with lysis buffer (wash buffer also containing 1% Triton X-100, 0.5% Na deoxycholate, and 0.1% Na dodecyl sulfate). Lysates were clarified by centrifugation at 100,000 x g for 30 min and stored at -80 C. Noninfected control cell cultures were treated in parallel, except that they were exposed to a sham inoculum (EMEM) during the interval when infected cultures were exposed to virus. The 35 S-labeled viral proteins were prepared from the attenuated strain of PRV, and the 14 C-labeled viral glycoproteins were prepared from the virulent strain. The routine use of the attenuated strain for preparing 35 S-labeled viral proteins was based on a preliminary study that indicated that it produced a greater concentration of many of the viruscoded proteins than did the virulent strain of PRV under the same in vitro conditions. However, because the attenuated strain does not code for the full complement of viral glycoproteins, l6 the virulent strain was used for preparation of 14 Clabeled glycoproteins. Viral glycoproteins present in 14 C-labeled lysates are referred to as cell associated.
Immunoprecipitation, electrophoresis, and molecular weight estimation. These procedures were as previously described, 14 except that the incubation intervals for immunoprecipitation were reduced from 2 hr to 30 min.
Treatment of pigs. Experiment 1. Each of 3 approximately 2-mo-old pigs of each of 3 treatment groups was vaccinated intramuscularly (IM) with 4 ml of the following types of PRV vaccine: Group 1, live attenuated virus; Group 2, inactivated attenuated virus; Group 3, inactivated virulent virus. Throughout the experiment, groups were housed separately in isolation rooms. At 3 wk after vaccination, all pigs were exposed oronasally (ON) to 5 ml (10 7.0 pfu/ml) of the virulent strain of PRV. At 19 wk after vaccination, 2 of 3 pigs of each group were started on a 5-day series of IM injections of dexamethasone (90 mg/pig/day). Nasal swabs were collected for virus isolation from all 9 pigs on the seventh through 11th days after the start of the series of dexamethasone injections. At 25 wk after vaccination, the same 2 of 3 pigs of each group previously treated with dexamethasone were given a 4-day series of dexamethasone injections (60 mg IM and 30 mg intravenously [IV]/pig/day). Nasal swabs were collected for virus isolation from all 9 pigs on the second through eighth day after the start of the series of dexamethasone injections. At 27 wk after vaccination, 2 of 3 pigs of each treatment group (1 of each group that had been given dexamethasone and 1 that had not) were necropsied. Trigeminal ganglia, tonsils, mandibular lymph nodes, and adrenals were collected for virus isolation. Additionally, 1 trigeminal ganglion of each pig was fixed in modified Carnoy's fixative (73.5% absolute ethanol, 24.5% glacial acetic acid, and 2% of a 37% formaldehyde solution) for 18 hr and then passed through a series of decreasing concentrations (100% to 70%) of ethanol in water. The fixed tissues were tested for in situ viral nucleic acid hybridization by methods previously described. 18 At 31 wk after vaccination, the 1 remaining pig of each treatment group was exposed ON (20 ml) and subcutaneously (40 ml) to the virulent strain of PRV (10 8.8 pfu/ ml). Throughout the experiment, pigs were observed daily for clinical signs, and blood samples were collected to test for serum antibodies to PRV before vaccination and at 3, 6, 12, 19, 22, 25, 27, 31, and 34 wk thereafter. Experiment 2. Each of 3 approximately 3-mo-old CDCD pigs of each of 3 treatment groups was vaccinated IM with the same types of vaccine described in experiment 1. Vaccine dosages were 2 ml for live-virus vaccine and 5 ml for inactivated-virus vaccines. An additional 4 CDCD pigs (Group 4) were included as nonvaccinated controls. Principals and controls were from the same 2 litters. Nonvaccinated control pigs, pigs vaccinated with attenuated virus, and pigs vaccinated with inactivated virus were housed separately in isolation rooms until 3 wk after vaccination when they were moved to 2 isolation rooms; 2 controls and either 4 or 5 vaccinates in each room. At 3 wk after vaccination, all pigs were exposed ON to 5 ml ( 10 7.9 pfu/ml) of the virulent strain of PRV. Rectal temperatures were taken daily until pigs either appeared clinically normal after reacting to challenge exposure (all vaccinates) or died (all nonvaccinates). At 10 wk after vaccination, 2 of 3 pigs of each vaccinated group were started on a 5-day series of dexamethasone injections; 30 mg IM and 30 mg IV in the morning and 60 mg IM in the afternoon to each pig. Nasal and tonsil swabs were collected from all 9 vaccinated pigs at the start of dexamethasone treatment and on the first through eighth, the 11th, and the 14th days thereafter. Throughout the experiment, pigs were observed daily for clinical signs, and blood samples were collected before vaccination and at 3, 6, 10, and 12 wk thereafter.
Virus isolation. A representative portion of each tissue examined was divided into 2 parts. One part was finely minced (≤ 1-mm 3 fragments) and added to an approximately 50% confluent monolayer of MVPK-1 cells so that about 10% of the culture was covered with tissue fragments. After 3 days of incubation at 37 C, nutrient medium was aspirated, the culture was gently rinsed to remove unattached tissue fragments, fresh nutrient medium was added, and the culture was again incubated at 37 C. Cultures were maintained for 2 wk, during which time they were observed daily for PRVinduced CPE. The other part of each tissue was triturated to prepare a 10% tissue suspension in EMEM. The suspension was clarified by centrifugation (1,000 x g, 10 min) and added at a ratio of 1:10 to the nutrient medium of a confluent monolayer of MVPK-1 cells. After 1 day of incubation at 37 C, the nutrient medium and tissue suspension were aspirated, fresh nutrient medium was added, and the culture was again incubated at 37 C. Cultures were maintained for 1 wk, during which time they were observed daily for CPE.
Plaque assay. Virus was diluted in lo-fold increments. Nutrient medium was then aspirated from confluent monolayers of MVPK-1 cells in 28-cm 2 petri dishes, and 0.2 ml of undiluted virus and each lo-fold dilution was added to each of 2 cultures. The inoculum was uniformly distributed over the culture surface, and virus was adsorbed for 1 hr at 37 C in a humid atmosphere of 5% CO, with occasional redistribution of inoculum. The inoculum was then aspirated and the cultures were each overlaid with 4 ml of nutrient medium containing 0.5% agar at 45 C. After solidification of the agar, culture plates were inverted and incubated at 37 C for 2-3 days in a humid atmosphere of 5% CO,. Plaques were counted and the virus titer expressed as pfu/ml. Nasal and tonsil swabs and virus assay. Swabs were immediately submerged in 2 ml of cold (4 C) EMEM containing gentamicin sulfate (500 µg/ml) and Amphotericin B (2 µg/ ml) in 13-x l00-mm screw-capped tubes. The tubes were kept on ice during transport and then frozen at -20 C. Tube contents were subsequently thawed and mixed vigorously. An aliquot of the liquid was diluted in lo-fold increments. One-tenth milliliter of undiluted liquid and 0.1 ml of each lo-fold dilution was added to each of 4 monolayer cultures at MVPK-1 cells in wells of a 96-well cell culture plate. Cultures were examined daily for virus-induced CPE. Titers are expressed as median cell culture infective doses (CCID 50 ).
Results
Immune response. The general pattern of immune responsiveness of pigs following vaccination, challenge of immunity with virulent virus, and treatment with dexamethasone to reactivate latent virus was as follows.
Virus neutralization: Pigs free of VN antibody for PRV before vaccination developed low levels of VN antibody following vaccination. Titers ranged from 2 to 32 (Tables 1, 2 ). Titers increased markedly after exposure to virulent virus, as much as 512-fold, and * All pigs were vaccinated at wk 0 and exposed oronasally to virulent virus at wk 3. † Two pigs of each vaccine group were treated with dexamethasone at wk 19 and 25. ‡ Two pigs of each vaccine group were killed at wk 27 and their tissues were tested for virus and viral nucleic acids (see text). The remaining pig of each vaccine group was exposed to a large dose (10 10.6 pfu) of virulent virus at wk 31. then usually decreased 2-8-fold during the interval between 3 weeks after exposure to virulent virus and treatment with dexamethasone; an interval of 13 weeks for experiment 1 and 4 weeks for experiment 2. After dexamethasone treatment, VN titers increased 16-fold for 2 (Nos. 89, 90) of the 12 dexamethasone-treated pigs collectively included in both experiments. The other 10 pigs treated with dexamethasone, as well as the 6 nontreated pigs, had little or no increase in VN titer (Tables 1, 2) . Two-fold increases in VN titer, which were determined for some nontreated as well as treated pigs, were considered within the range of random variation and experimental error. A second dexamethasone treatment (experiment 1) had little or no affect on VN titer (Table 1 ). However, exposure of 3 pigs previously treated twice with dexamethasone to a large dose (10 10.6 pfu) of virulent virus was followed by a 4-8-fold increase in neutralizing activity ( Table 1) .
Immunoprecipitation of 35 S-labeled viral proteins: Seroconversion of pigs following vaccination with either attenuated-or inactivated-virus vaccines was not as clearly defined by immunoprecipitation of 35 S-labeled viral proteins as by VN. Most sera collected before vaccination had a low level of precipitating activity for 1 or more 35 S-labeled viral proteins. As a consequence, the immune response to vaccination was dependably evaluated only by side-by-side comparison of sera collected from the same pig (Fig. 1) . Reactions were mainly with 1 or more of 5 viral proteins ranging in molecular weight from about 59K to 123K; with the strongest response (11 of 18 pigs) usually to a viral protein of about 103K. However, the precipitation patterns varied widely in regard to both the number and amount of proteins precipitated, and 1 pig (No. 89) had a barely perceptible increase in precipitating activity after vaccination. This variability can be appreciated by comparing lane 3 (i.e., sera collected 3 weeks after vaccination) of 5 pigs (Figs. 1, 2) . Subsequent challenge exposure of vaccinated pigs to virulent virus resulted in an enhancement of the immune response that was reflected in an increase in both the number and amount of viral proteins precipitated. However, * All pigs were vaccinated at wk 0 and exposed oronasally to virulent virus at wk 3. † Two pigs of each vaccine group were treated with dexamethasone at wk 10. for all but 2 pigs, 1 (No. 91) that had an unusually 3 (experiment 1) or 2 (experiment 2) weeks later (Fig. strong immune response to challenge exposure and 1 1). The increase in precipitating activity of sera col-(No. 93) that appeared to have had an additional an-lected after dexamethasone treatment usually appeared tigenic stimulus between 12 and 19 weeks after vac-proportionately greater for viral proteins of lower mocination ( Fig. 2) , precipitating activity was still limited lecular weights (<46K). The change in precipitation mainly to viral proteins of relatively high molecular pattern was most striking for a viral protein of about weight (≥59Κ). Precipitation patterns remained es-45.7K (Fig. l) , which appeared to correspond to a sentially unchanged throughout the remainder of the prominent viral protein in 35 S-labeled infected-cell lyexperiments unless pigs were either treated with dexa-sates ( Fig. 3) . A second dexamethasone treatment (exmethasone or again exposed to virulent virus. For 11 periment 1) did not cause any apparent additional enof the 12 pigs treated with dexamethasone (the excep-hancement of the immune response, whereas tion was pig No. 93), such treatment resulted in an subsequent exposure to a large dose of virulent virus enhancement of precipitating activity of sera collected did (Fig. 4A ). ulent virus. However, viral nucleic acid sequences were identified in neurons of trigeminal ganglia of 3 pigs (Nos. 91, 97, 99) by nucleic acid hybridization. Hybridization was suspect for another pig (No. 98) and absent or at a subdetectable level for the remaining 2 pigs (Nos. 96, 100). There was no clear correlation between the results of hybridization and previous history in regard to either type of vaccine or dexamethasone treatment.
Discussion
A similar and progressive increase in immune responsiveness of pigs paralleled their sequential exposure to PRV by vaccination, oronasal exposure to virulent virus, and virus reactivation. Quantitative changes in serum antibodies of different antigenic specificities were clearly defined by RIP. Each exposure to virus resulted in an increase in the number and amount of virus-coded proteins that were identified.
The immune responses after vaccination and challenge were directed primarily to virus-coded proteins of relatively high molecular weight, whereas those following virus reactivation appeared proportionately greater for lower molecular weight (<46K) proteins. We assume that these events reflect the normal progression of immune responses to repeated exposures to virus; however, the possibility that virus reactivation is associated with some unique immunologic features was not excluded.
The overall results of the study were similar regardless of the type of vaccine used for initial immunization. Each of the vaccines raised a measurable amount of VN antibody, and all seemed to provide a similar level of protection against challenge with virulent virus. The clear response to viral glycoproteins following exposure of vaccinated pigs to virulent virus was of particular interest in that all deletion-mutant vaccines currently available are characterized by the absence of 1 or more glycoproteins. 7, 9, 25, 26 Because the identification of vaccinated pigs that have also been exposed to virulent virus depends on the ability of the deleted (diagnostic) protein to raise antibody under a variety of conditions, this protein must be highly antigenic. Extensive field use of the current vaccines will determine if they meet this criterion. Notice that several nonglycosylated proteins appeared to be highly antigenic in that they were precipitated by postvaccination as well as postchallenge sera. It is conceivable that further characterization of these proteins could indicate their use as diagnostic antigens, especially in conjunction with subunit vaccines. The increase in serum RIP activity of 11 of 12 pigs after their first treatment with dexamethasone was interpreted as a consequence of virus reactivation. Reactivation was confirmed for 4 of the 12 pigs by isolation of virus from nasal swabs. The other treated pigs may have either failed to shed detectable amounts of virus or shed virus at times other than when swabs were collected. In either case, however, we question the means by which sufficient virus spread from nervous tissues to cause the observed immune response. An explanation may rest with the possibility that PRV can establish latency in lymphoid as well as nervous tissues. 19 Collectively, the results indicate that RIP may provide an additional epizootiologic tool to identify naturally occurring reactivation. We believe that pig No. 93 (Fig. 2) is an example. Moreover, RIP may provide the only evidence for reactivation when there is little or no concurrent virus shedding or increase in serum VN titer. The value of RIP under these circumstances was demonstrated during a recent study in which pigs were initially infected with PRV while partially pro-12. McFerran JB, Dow C: 1975, Studies on immunization of pigs tected by passively acquired (maternal) antibody. 13 with Bartha strain of Aujeszky's disease virus. Res Vet Sci 19: 17-22.
